JAZZ
NasdaqJazz Pharmaceuticals plc
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$3.1B
2021
$3.7B
2022
$3.8B
2023
$4.1B
2024
$4.3B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$4.3B
Net Income$-356.1M
Gross Profit—
Oper Income$-430.2M
EPS (dil)$-5.84
Rev/sh$68.02
FCF/sh$20.67
Book/sh$68.83
Gross M—
Oper M-10.1%
Profit M-8.3%
FCF M30.4%
ROE-8.2%
ROA-3.1%
ROIC-2.6%
R&D/Rev7.0%
Rev Y/Y4.9%
Rev 3Y CAGR5.3%
EPS Y/Y-167.5%
EPS 3Y CAGR—
FCF 3Y CAGR1.4%
Payout—
Div/sh—
Shs Chg Y/Y-7.6%
Current Ratio1.86
Quick Ratio1.67
Debt/Eq1.48
Int Coverage-256.9×
Net Debt$5.0B
Total Debt$6.4B
Cash & Eq$1.4B
Total Assets$11.7B
Oper CF$1.4B
Capex$58.8M
Free CF$1.3B
Buybacks$125.0M
Equity$4.3B
Liabilities—
Shs Outstand0.06B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.1B | $3.7B | $3.8B | $4.1B | $4.3B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $170.3M | $-65.5M | $578.6M | $716.6M | $-430.2M |
| Net Income | $-329.7M | $-224.1M | $414.8M | $560.1M | $-356.1M |
| Diluted EPS | $-5.52 | $-3.58 | $6.10 | $8.65 | $-5.84 |
| Operating Cash Flow | $778.5M | $1.3B | $1.1B | $1.4B | $1.4B |
| Free Cash Flow | $750.9M | $1.2B | $1.1B | $1.4B | $1.3B |
COMMUNITY · $JAZZ0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.